GlassScriptPhysician profile
Benjamin M Goldstein
NPI 1811919228
$5,096.63
in general payments reported to CMS, 2019-2025
38 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $979 · 2020: $589 · 2021: $1,471 · 2022: $1,813 · 2023: $159 · 2024: $86.44.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $245.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $245.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $732.10 | 2019-2022 | |
| Abbvie INC. | $707.26 | 2021-2024 | |
| Novo Nordisk INC | $652.17 | 2019-2022 | |
| Pfizer INC. | $366.85 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $306.28 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $231.74 | 2022 | |
| Janssen Pharmaceuticals, INC | $220.81 | 2020-2022 | |
| Amarin Pharma, INC. | $186.34 | 2020-2021 | |
| Eisai INC. | $179.12 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $164.50 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $130.44 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $125.00 | 2021 | |
| Amgen INC. | $120.53 | 2019-2022 | |
| Abbott Laboratories | $116.05 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $102.45 | 2019-2022 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $91.65 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $82.04 | 2020-2022 | |
| Glaxosmithkline, LLC. | $78.36 | 2019-2022 | |
| Sanofi Pasteur INC. | $56.24 | 2019-2020 | |
| Allergan, INC. | $51.02 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $50.44 | 2022 | |
| Novartis Pharmaceuticals Corporation | $36.45 | 2021-2022 | |
| Ge Healthcare | $30.71 | 2019 | |
| Shield Therapeutics INC | $30.54 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $27.73 | 2019-2022 | |
| Alkermes, INC. | $24.60 | 2024 | Lybalvi |
| Lundbeck LLC | $22.31 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.16 | 2022 | |
| Bausch Health US, LLC | $19.67 | 2022 | |
| Dynavax Technologies Corporation | $17.58 | 2022 | |
| Optinose US, INC. | $16.98 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $15.62 | 2022 | |
| Ironwood Pharmaceuticals, INC | $15.22 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $14.62 | 2019 | |
| Idorsia Pharmaceuticals US INC | $13.62 | 2022 | |
| Currax Pharmaceuticals LLC | $13.30 | 2022 | |
| Amneal Pharmaceuticals LLC | $13.20 | 2022 | |
| Esperion Therapeutics, INC. | $12.93 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Goldstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.